Despite the introduction of pneumococcal conjugate vaccine (PCV) in the childhood immunization program in New Zealand, the incidence of invasive pneumococcal disease in neonates (<30 days old) remains relatively high at 6 per 100,000 (versus 2/100,000 in the U.S.). Out of 19 cases in infants <30 days old in this study, 9 (47%) occurred during the first 7 days of life and 6 within the first 48 hours. If proven effective, maternal vaccination would cover 74% to 84% of the serotypes that infected these infants, depending on the vaccine.
Full Citation:
Mount V, Burton C, Jackson C et al.. 2017. Neonatal invasive pneumococcal disease: New Zealand experience in the era of pneumococcal vaccination. Australian and New Zealand Journal of Obstetrics and Gynaecology. 57(3).
Title of Article: Neonatal invasive pneumococcal disease: New Zealand experience in the era of pneumococcal vaccination
Author(s): Mount V, Burton C, Jackson C et al.
Publication Year: 2017
Publication Name: Australian and New Zealand Journal of Obstetrics and Gynaecology
Publication Volume: 57(3)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pubmed/27530965
DOI (Digital Object Identifier): 10.1111/ajo.12512
Topics: Health
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Immunization Terms: Maternal immunization
Countries: New Zealand
WHO Regions: Western Pacific